Americans’ Challenges with Health Care Costs

Authors: Grace Sparks, Lunna Lopes, Alex Montero, Marley Presiado, and Liz Hamel
Published: Jul 11, 2025

This brief was updated on July 11, 2025 to include the latest KFF polling data.

For many years, KFF polling has found that the high cost of health care is a burden on U.S. families, and that health care costs factor into decisions about insurance coverage and care seeking. These costs and the prospect of unexpected medical bills also rank as the top financial worries for adults and their families. This data note summarizes recent KFF polling on the public’s experiences with health care costs. Main takeaways include:

  • Just under half of U.S. adults say it is difficult to afford health care costs, and one in four say they or a family member in their household had problems paying for health care in the past 12 months. Black and Hispanic adults, those with lower incomes, and the uninsured are particularly likely to report problems affording health care in the past year.
  • The cost of health care can lead some to put off needed care. About one-third (36%) of adults say that in the past 12 months they have skipped or postponed getting health care they needed because of the cost. Notably three in four (75%) uninsured adults under age 65 say they went without needed care because of the cost.
  • The cost of prescription drugs prevents some people from filling prescriptions. About one in five adults (21%) say they have not filled a prescription because of the cost while a similar share (23%) say they have instead opted for over-the-counter alternatives. About one in seven adults say they have cut pills in half or skipped doses of medicine in the last year because of the cost. A third of all adults say they have taken at least one of these cost saving measures in the past year, including larger shares of women and those with lower incomes.
  • Health care debt is a burden for a large share of Americans. In 2022, about four in ten adults (41%) reported having debt due to medical or dental bills including debts owed to credit cards, collections agencies, family and friends, banks, and other lenders to pay for their health care costs, with disproportionate shares of Black and Hispanic adults, women, parents, those with low incomes, and uninsured adults saying they have health care debt.
  • Those who are covered by health insurance are not immune to the burden of health care costs. Almost four in ten insured adults under the age of 65 (38%) worry about affording their monthly health insurance premium and large shares of adults with employer-sponsored insurance (ESI) and those with Marketplace coverage rate their insurance as “fair” or “poor” when it comes to their monthly premium and to out-of-pocket costs to see a doctor.
  • Notable shares of adults say they are worried about affording medical costs such as the cost of health care services (including out-of-pocket costs not covered by insurance, such as co-pays and deductibles) or unexpected bills. About six in ten adults say they are either “very” or “somewhat worried” about being able to afford the cost of health care services (62%) or unexpected medical bills (61%) for themselves and their families.

Difficulty Affording Medical Costs

Many U.S. adults have trouble affording health care costs. While lower income and uninsured adults are the most likely to report this, those with health insurance and those with higher incomes are not immune to the high cost of medical care. Just under half of U.S. adults say that it is very or somewhat difficult for them to afford their health care costs (44%). Uninsured adults under age 65 are much more likely to say affording health care costs is difficult (82%) compared to those with health insurance coverage (42%). Additionally, a slight majority of Hispanic adults (55%) and half of Black adults (49%) report difficulty affording health care costs compared to about four in ten White adults (39%). Adults in households with annual incomes under $40,000 are more likely than adults in households with higher incomes to say it is difficult to afford their health care costs. (Source: KFF Health Tracking Poll: May 2025)

Nearly Half of Adults Say It Is Difficult To Afford Health Care Costs, Including Large Shares of the Uninsured, Black and Hispanic Adults, and Those With Lower Incomes

When asked specifically about problems paying for health care in the past year, about one in four (23%) adults say they or a family member in their household had problems paying for care, including three in ten Hispanic adults (33%) and Black adults (30%). Over half (55%) of uninsured adults under age 65 say they or a family member in their household had problems paying for health care, compared to just one in five (22%) insured adults. (Source: KFF Health Tracking Poll: May 2025)

Reports of Problems Paying for Health Care Highest Among Hispanic and Black Adults and the Uninsured

The cost of care can also lead some adults to skip or delay seeking services, with one-third (36%) of adults saying that they have skipped or postponed getting needed health care in the past 12 months because of the cost. Women are more likely than men to say they have skipped or postponed getting health care they needed because of the cost (38% vs. 32%). Adults ages 65 and older, most of whom are eligible for health care coverage through Medicare, are much less likely than younger age groups to say they have not gotten health care they needed because of cost.

Three-quarters of uninsured adults say they have skipped or postponed getting the health care they needed due to cost. Having health insurance, however, does not offer ironclad protection as about four in ten adults with insurance (37%) still report not getting health care they needed due to cost. (Source: KFF Health Tracking Poll: May 2025)

Three-Quarters of Uninsured Adults Say They Have Skipped or Postponed Getting Health Care They Needed in the Past 12 Months Due to Cost

Skipping care due to costs can have notable health impacts. Nearly two in ten adults (18%) report that their health got worse because they skipped or delayed getting care. Among adults under age 65, those who are uninsured are twice as likely as those with health coverage to say that their health worsened due to skipped or postponed care (42% vs. 20%). About four times as many adults under age 65 (23%) say their health got worse after skipping or postponing care as adults ages 65 and older (6%), most of whom have Medicare coverage. (Source: KFF Health Tracking Poll: May 2025)

Nearly Two in Ten Report Their Health Got Worse After Skipping or Postponing Care Due to Cost

A 2022 KFF report found that people who already have debt due to medical or dental care are disproportionately likely to put off or skip medical care. Half (51%) of adults currently experiencing debt due to medical or dental bills say in the past year, cost has been a probititor to getting the medical test or treatment that was recommended by a doctor. (Source: KFF Health Care Debt Survey: Feb.-Mar. 2022)

Prescription Drug Costs

The high cost of prescription drugs also leads some people to cut back on their medications in various ways. About one in four adults (23%) say in the past 12 months they have taken an over-the-counter drug instead of getting a prescription filled because of cost concerns and about one in five (21%) say they have not filled a prescription due to the cost. Additionally, about one in seven adults (15%) say that in the past 12 months they have cut pills in half or skipped doses of medicine due to cost.

One-third of the public (33%) say they have taken any of these cost saving measures in the past 12 months. Four in ten women (39%) say they have taken any of these prescription medication measures compared to one-quarter (26%) of men. Additionally, just under half of Hispanic adults (46%) say they’ve either taken an over-the-counter drug, skipped doses, or not filled prescriptions because of the cost, compared to three in ten (29%) White adults who say the same. Similarly, larger shares those with lower incomes report having taken a cost-saving measure in the last year compared to those with higher incomes (41% of those with a household income of less than $40,000 a year vs. 29% of those with an income of $40,000 or more). (Source: KFF Health Tracking Poll: May 2025)

Notably, adults with chronic conditions, who tend to have higher health care and medication needs, can often face challenges affording prescriptions. In KFF’s 2023 Survey of Consumer Experiences with Health Insurance, insured adult with a chronic condition were twice as likely as those without a chronic condition to say they had delayed or gone without prescription drugs due to the cost (18% vs. 9%).

About Two in Ten Adults Say They Have Not Filled a Prescription or Taken an Over-the-Counter Drug Instead Due to Cost

Health Insurance Cost Ratings

Health insurance provides some financial protection, but premiums and out-of-pocket costs can still present a financial burden for many individuals. Overall, most insured adults rate their health insurance as “excellent” or “good” when it comes to the amount they have to pay out-of-pocket for their prescriptions (61%), the amount they have to pay out-of-pocket to see a doctor (53%), and the amount they pay monthly for insurance (54%). However, at least three in ten rate their insurance as “fair” or “poor” on each of these metrics, and affordability ratings vary depending on the type of coverage people have.

Adults who have private insurance through employer-sponsored insurance or Marketplace coverage are more likely than those with Medicare or Medicaid to rate their insurance negatively when it comes to their monthly premium, the amount they have to pay out of pocket to see a doctor, and their prescription co-pays. About one in four adults with Medicare give negative ratings to the amount they have to pay each month for insurance and to their out-of-pocket prescription costs, while about one in five give their insurance a negative rating when it comes to their out-of-pocket costs to see a doctor.

Medicaid enrollees are less likely than those with other coverage types to give their insurance negative ratings on these affordability measures (Medicaid does not charge monthly premiums in most states, and copays for covered services, where applied, are required to be nominal). (Source: KFF Survey of Consumer Experiences with Health Insurance)

Large Shares of Adults With ESI and Marketplace Coverage Rate Their Insurance Negatively When It Comes to Premiums and Out-of-Pocket Costs

Health Care Debt

In June 2022, KFF released an analysis of the KFF Health Care Debt Survey, a companion report to the investigative journalism project on health care debt conducted by KFF Health News and NPR, Diagnosis Debt. This project found that health care debt is a wide-reaching problem in the United States and that 41% of U.S. adults currently have some type of debt due to medical or dental bills from their own or someone else’s care, including about a quarter of adults (24%) who say they have medical or dental bills that are past due or that they are unable to pay, and one in five (21%) who have bills they are paying off over time directly to a provider. One in six (17%) report debt owed to a bank, collection agency, or other lender from loans taken out to pay for medical or dental bills, while similar shares say they have health care debt from bills they put on a credit card and are paying off over time (17%). One in ten report debt owed to a family member or friend from money they borrowed to pay off medical or dental bills.

While four in ten U.S. adults have some type of health care debt, disproportionate shares of lower income adults, the uninsured, Black and Hispanic adults, women, and parents report current debt due to medical or dental bills.

Four in Ten Adults Currently Have Debt Due to Medical or Dental Bills

Vulnerabilities and Worries About Health Care and Long-Term Care Costs

KFF’s May 2025 Health Tracking Poll shows the cost of health care services and unexpected medical bills are at the top of the list of people’s financial worries, with about six in ten saying they are at least somewhat worried about affording the cost of health care services (62%) or unexpected medical bills (61%) for themselves and their families. These are larger than the shares who say they worry about affording housing costs (51%), transportation expenses (50%), utilities (49%), and food (48%) for their families.

Notably, eight in ten uninsured adults under age 65 say they are worried about affording the cost of health care services or unexpected medical bills (82% and 80%, respectively). About four in ten (38%) insured adults under the age of 65 say they are worried about affording their monthly health insurance premium. (Source: KFF Health Tracking Poll: May 2025)

Two-Thirds of Adults Say They Are Worried About Being Able To Afford the Cost of Health Care, Unexpected Medical Bills

Many U.S. adults may be one unexpected medical bill from falling into debt. About half of U.S. adults say they would not be able to pay an unexpected medical bill that came to $500 out of pocket. This includes one in five (19%) who would not be able to pay it at all, 5% who would borrow the money from a bank, payday lender, friends or family to cover the cost, and one in five (21%) who would incur credit card debt in order to pay the bill. Women, those with lower household incomes, Black and Hispanic adults are more likely than their counterparts to say they would be unable to afford this type of bill. (Source: KFF Health Care Debt Survey: Feb.-Mar. 2022)

About Half of Adults Would Be Unable To Pay for an Unexpected $500 Medical Bill in Full, Including Larger Shares of Women, Those With Lower Household Incomes, Black and Hispanic Adult

Among older adults, the costs of long-term care and support services are also a concern. Almost six in ten (57%) adults 65 and older say they are at least “somewhat anxious” about affording the cost of a nursing home or assisted living facility if they needed it, and half say they feel anxious about being able to afford support services such as paid nurses or aides. These concerns also loom large among those between the ages of 50 and 64, with more than seven in ten saying they feel anxious about affording residential care (73%) and care from paid nurses or aides (72%) if they were to need these services. See The Affordability of Long-Term Care and Support Services: Findings from a KFF Survey for a deeper dive into concerns about the affordability of nursing homes and support services.

Medicare at 60: A Popular Program Facing Challenges

Published: Jul 10, 2025

In this article in the Journal of Health Politics, Policy and Law, KFF’s Tricia Neuman, Jeannie Fuglesten Biniek and Juliette Cubanski examine three isssues facing Medicare’s future: privatization, affordability and spending/financing.

They write that as Medicare approaches its 60th anniversary, it almost goes without saying that the program is both popular and successful. Medicare provides health insurance coverage to 67 million older adults and people with disabilities. Medicare is viewed favorably by Democrats, Republicans, and independents. Medicare has also helped to extend life expectancy and, in conjunction with the Civil Rights Act of 1964, narrow disparities in care. It is a vital source of revenue for hospitals, physicians and other health care providers, and health insurers, and it is an essential component of health and retirement security in the United States. These are among the reasons why Medicare is often considered a third rail in politics.

The authors also note that Medicare also faces challenges stemming from the growing role of private plans, demographic shifts, and rising health care costs. They examine these challenges by focusing on three fundamental questions: What are the implications of the transformation taking place such that private insurers are playing a more dominant role in providing Medicare benefits? What changes may be important for addressing the gaps in covered benefits and related affordability challenges? And how can Medicare be sustained to finance care for current and future generations?

Access to OB-GYNs: Evaluating Workforce Supply and ACA Marketplace Networks

Published: Jul 10, 2025

OB-GYNs provide a range of care for women throughout their lifespan, including diagnosis and treatment of gynecological conditions such as endometriosis, polycystic ovary syndrome, and cervical cancer; contraceptive care; prenatal and postpartum care; and menopause management. Access to care depends on several factors, including the availability of providers and, for people with insurance, whether the provider is in their plan’s network. When there are few providers in an area, local providers are not taking new patients, or a patient needs to see a provider who is not in their plan’s network, their ability to get care, how long they have to wait for an appointment, and potentially how much they have to pay out-of-pocket can all be impacted.

This brief examines the supply of OB-GYNs in the U.S. and the share of OB-GYNs participating in the provider networks of Qualified Health Plans (QHPs) offered in the individual market in the federal and state Affordable Care Act (ACA) Marketplaces in 2021. This analysis uses multiple data sources; see the Methods section for details. While many more women are covered by employer-sponsored health plans than ACA Marketplace plans, there is no publicly available data to analyze the networks for employer plans.

Key Takeaways

  • There were 38 practicing OB-GYNs per 100,000 women in the United States, with higher ratios in metro counties (41) than in rural counties (13) in 2021-2022. 38 practicing OB-GYNs per 100,000 women is equivalent to one OB-GYN per about 2,600 women.
  • Nearly half (48%) of counties did not have any practicing OB-GYNs and 7% of women lived in a county with no OB-GYN. The share of women with no OB-GYN in their county was substantially higher in rural counties than in metro counties (58% vs. 3%).
  • In 2021, enrollees in ACA Marketplace plans had in-network access to 55% of practicing OB-GYNs in their area on average. By comparison, Marketplace enrollees had in-network access to 43% of primary care physicians.
  • Marketplace enrollees in metro counties, on average, had in-network access to 53% of the OB-GYNs near their home compared to 70% in rural counties. However, as noted above, there are relatively few OB-GYNs practicing in rural counties.
  • On average, Marketplace enrollees in counties with the highest shares of people of color had in-network access to 43% of area OB-GYNs while those in counties with the lowest shares of people of color had in-network access to 69%.

OB-GYN Workforce

OB-GYNs play an important role in ensuring women have access to comprehensive health care. There are many factors that can create barriers to accessing obstetric and gynecological care, including the size of the OB-GYN workforce and the ratio of OB-GYNs to patients. Although there is no established “adequacy” ratio of OB-GYNs to patients, OB-GYN shortages could be considered in the context of longer appointment wait times and increased travel distances, among others. The U.S. Department of Health and Human Services projects a shortage of 7,980 OB-GYNs by 2037 based on the supply of OB-GYNs in the workforce and the demand for OB-GYNs (based on the population of adolescent girls and women).

According to KFF analysis of the HRSA Area Health Resource Files for 2021-2022, there were 38 OB-GYNs per 100,000 women ages 15-64 (hereafter collectively referred to as “women”) in the United States, with wide variation by county (Figure 1). The workforce data analyzed here is from the year that Roe v. Wade was overturned (and the year before), so that decision’s specific impacts on the OB-GYN workforce are largely not reflected in this data.

Number of Practicing OB-GYNs per 100,000 Women Ages 15-64, by County, 2021-2022

In 2021-2022, nearly half (48%) of U.S. counties did not have any OB-GYNs, and 7% of women lived in a county with no OB-GYN. Three-quarters (74%) of all counties had fewer than five OB-GYNs, and 17% of women lived in a county with fewer than five OB-GYNs.

The number of OB-GYNs per 100,000 women was higher than the national average in 28 of the top 30 Core-Based Statistical Areas (CBSAs) with the largest number of women (Figure 2). Among these 30 CBSAs, the CBSAs with the highest ratios were San Francisco-Oakland-Berkeley, CA; Baltimore-Columbia-Towson, MD; and Portland-Vancouver-Hillsboro, OR-WA, with 61, 53, and 53 OB-GYNs per 100,000 women, respectively. The CBSAs with the lowest ratios were Columbus, OH; Los Angeles-Long Beach-Anaheim, CA; and Virginia Beach-Norfolk-Newport News, VA-NC, with 39, 38, and 33 OB-GYNs per 100,000 women, respectively.

CBSA is the umbrella term for Metropolitan and Micropolitan Statistical Areas as defined by the Office of Management and Budget (OMB). CBSAs consist of the county or counties or equivalent entities associated with at least one urban core (urbanized area or urban cluster) of at least 10,000 population, plus adjacent counties having a high degree of social and economic integration with the core as measured through commuting ties with the counties containing the core.

Number of OB-GYNs per 100,000 Women in the Top 30 Core-Based Statistical Areas With the Largest Number of Women, 2021-2022

County Classification Differences in Provider Availability

In 2021-2022, eight in ten (79%) rural counties had no OB-GYNs and nearly six in ten (58%) women in rural counties lived in a county without an OB-GYN (Table 1). There were approximately three times more OB-GYNs per 100,000 women in metro counties (42) than in rural counties (13).

County classifications are based on USDA’s 2013 Rural-Urban Continuum Codes and KFF categorized these classifications into metro counties, small urban counties, and rural counties. See the Methods section for more details. Using this taxonomy, 85% of women lived in metro counties, 11% lived in small urban counties, and 4% lived in rural counties.

Race/Ethnicity Differences in Provider Availability

Counties with an above-average share of White non-Hispanic people had almost half the number of OB-GYNs per 100,000 women as counties with an above-average share of Black non-Hispanic people (24 vs. 46). There were 41 OB-GYNs per 100,000 women in counties with an above-average share of Hispanic people of any race. On average, about 58% of the U.S. population was White non-Hispanic, 12% was Black non-Hispanic, and 19% was Hispanic (any race) during that timeframe.

Share of Counties With No OB-GYNs and Share of Women Living in Them, by County Demographics, 2021-2022

Other Implications

Provider shortages can also play a role in hospital and clinic staffing. For example, one study found that more than 35% of counties are considered “maternity care deserts,” meaning that there is no access to birthing hospitals, birth centers offering obstetric care, or obstetric providers. Maternity care deserts affected maternity care for more than 2.3 million women of reproductive age in 2022, resulting in poorer health outcomes, less prenatal care, and higher rates of pre-term births. Additionally, another study found that the share of hospitals in the U.S. without obstetric services increased from approximately 35% in 2010 to 42% in 2022, with even higher percentages for rural hospitals. Studies have identified that workforce challenges are one of the primary reasons for labor and delivery units closing in rural hospitals.

Although it is not clear how, precisely, OB-GYN workforce shortages impact the use of obstetric and gynecological care, the overall disparities in maternal and infant health for women of color are well-documented. While increased attention to these disparities has contributed to a range of federal and state efforts to reduce disparities in maternal and infant health, it is unclear how, or if, these efforts will continue in a political landscape characterized by rolling back efforts aimed at identifying and addressing disparities in historically marginalized groups and eliminating agencies and committees that lead these efforts. Additionally, state abortion bans and restrictions may exacerbate poor maternal and infant health outcomes, especially for people of color.

Additionally, it is reported that 1.2 million reproductive-age women live in a county without a single health center offering the full range of contraceptive methods, referred to as a “contraceptive desert.” A 2023 KFF survey of OB-GYNs following the overturning of Roe v. Wade found that just three in ten (29%) OB-GYNs provide all contraceptive methods, and that share is substantially lower in states that had banned abortion (13%). Although most OB-GYNs do not provide abortion services, abortion bans could also exacerbate provider shortages in some areas and impact access to other types of care that OB-GYNs provide.

OB-GYN Provider Networks in Marketplace Plans

The breadth of provider networks in the Affordable Care Act (ACA) Marketplaces has been the subject of significant policy interest. As insurers seek to offer lower-premium plans, one mechanism for controlling costs is to limit their physician networks to providers with lower payment rates. While the Centers for Medicare and Medicaid Services (CMS) establishes minimum standards for the adequacy of physicians, including OB-GYNs, in Marketplace plan networks, insurers retain considerable flexibility in how they design networks.

While many more women are covered by employer-sponsored health plans than ACA Marketplace plans, there is no publicly-available data to analyze the networks for employer plans.

The 2023 KFF Survey of Consumer Experiences with Health Insurance found that 24% of adult women with Marketplace coverage said that in the past year, a particular doctor (not specific to obstetric or gynecological care) or hospital they needed was not covered by their insurance. Among women Marketplace enrollees who experienced this problem, 32% said that needed care was delayed, and 42% said they ended up paying more out of pocket for care than expected as a result of problems they had with their health insurance.

This section analyzes OB-GYN provider networks of Qualified Health Plans (QHPs) offered in the individual health insurance Marketplaces in 2021. (At the time of analysis, 2021 was the most recent data available for calculating the total number of active OB-GYNs. See the Methods section for more details.) In total, 12 million consumers selected a plan for the 2021 plan year, roughly 55% of whom were women. Due to missing or incomplete demographic data for some states, this analysis presents data for Marketplace enrollees of all genders.

On average, Marketplace enrollees had in-network access to more than half (55%) of the practicing OB-GYNs near their homes in 2021 (Figure 3). By comparison, Marketplace enrollees had in-network access to 43% of primary care physicians and 37% of psychiatrists near their homes. One-quarter of enrollees were enrolled in plans with fewer than 34% of the local OB-GYNs in-network, while another quarter were in plans with at least 78% of local OB-GYNs in-network.

Share of Local OB-GYNs Included in Marketplace Enrollees’ Provider Networks, 2021

Geographic Differences in Marketplace Provider Networks

While metro counties had more practicing OB-GYNs overall, smaller shares of them participated in Marketplace plan networks compared to OB-GYNs in small urban and rural counties (Figure 4). Eighty-eight percent of Marketplace enrollees lived in a metro county. Marketplace enrollees in metro counties, on average, had access to 53% of the OB-GYNs within five to ten miles of their county through their plan networks, with one-quarter enrolled in a plan whose network included no more than 33% of local OB-GYNs.

Marketplace enrollees in rural counties (e.g., Knox County, ME; Anderson County, TX; Macon County, NC), on average, had access to 70% of OB-GYNs in their local area (within 30 miles) through their plan networks. The higher OB-GYN participation rates in these counties, however, should be considered in the context of the small number of OB-GYNs practicing in these areas. For example, 98% of rural counties had fewer than five practicing OB-GYNs. It is possible that not all of these providers are accepting new patients, and an enrollee’s choice may be even more limited than the number of OB-GYNs who participate in the plan network. (See the OB-GYN Workforce section for county classification definitions.)

Share of OB-GYNs in Marketplace Enrollees' Provider Networks, by County Classification, 2021

The 30 counties with the highest enrollment in the Marketplaces in 2021 collectively represented 34% of all Marketplace enrollees and 21% of the U.S. population. Most of them are urban and some are home to large cities (e.g., Seattle in King County, WA). On average, Marketplace enrollees in almost all of these counties were in plans that included fewer than half of local OB-GYNs, though there was significant variation across these 30 counties (Figure 5). For example, Marketplace enrollees in Cook County, IL (Chicago) had access to fewer than two in ten (20%) OB-GYNs in their area on average. In contrast, enrollees in Gwinette County, GA (outside Atlanta) had in-network access to seven in ten (71%) practicing OB-GYNs on average.

Average Share of OB-GYNs Participating in Marketplace Networks in the 30 Counties With the Most Marketplace Enrollment, by County, 2021

Race/Ethnicity Differences in Marketplace Provider Networks

On average, Marketplace enrollees living in counties with a higher share of people of color were in networks that included a smaller share of OB-GYNs than counties with a smaller share of people of color (Figure 6). The quarter of Marketplace enrollees living in the counties with the highest share of people of color had access to 43% of OB-GYNs in-network, on average, compared to 69% in counties with the smallest share of people of color. These differences may reflect the higher concentrations of these people of color in large metro counties, where plans typically had narrower provider networks. ‘People of color’ include those who identify as Hispanic (of any race), multi-racial (Hispanic or non-Hispanic), or a race other than White (Hispanic or non-Hispanic).

Average Share of OB-GYNs Included in Marketplace Plan Networks, by Share of People of Color in County, 2021

Numbers of Practicing and In-Network OB-GYNs

The share of providers participating in a network is just one component of access and may not always gauge how well enrollees are served. High network participation rates matter little if there are few local providers to begin with. For example, in 2021, about one-quarter (23%) of Marketplace enrollees lived in a county with fewer than 25 practicing OB-GYNs in the local area (Figure 7). One in ten (10%) Marketplace enrollees had fewer than 10 practicing OB-GYNs in the local area, and 4% lived in a county with fewer than five OB-GYNs in the area (0% of Marketplace enrollees lived in a county with no local OB-GYNs). Sixty-three percent of Marketplace enrollees live in a county with 25 or more practicing OB-GYNs.

When it comes to network breadth, more than one-third (36%) of Marketplace enrollees were in a plan that included fewer than 25 local OB-GYNs, either because there weren’t 25 OB-GYNs in the market, or because available OB-GYNs were not included in the network. Nearly two in ten (18%) were in a plan that included fewer than ten OB-GYNs and one in ten (10%) were in a plan that had fewer than five local OB-GYNs (including 1% who were in a plan with no OB-GYNs). Thirty-five percent of Marketplace enrollees were in a plan with 25 or more OB-GYNs.

Among Marketplace Enrollees, Supply of Practicing OB-GYNs and OB-GYNs Participating in Marketplace Plan Networks, 2021

Although this OB-GYN network analysis is just among ACA Marketplace plans, employer-sponsored plans, which cover more people than Marketplace plans, also have provider networks. While many employers describe their plan’s provider networks as “very broad” or “somewhat broad,” nearly 1-in-5 (18%) firms with 5,000 or more workers characterize their plan as “somewhat narrow” or “very narrow.” The extent to which provider networks reduce the availability of OB-GYN services for those with employer coverage, and for which enrollees, remains unclear.

This work was supported in part by a grant from the Robert Wood Johnson Foundation. The views and analysis contained here do not necessarily reflect the views of the Foundation. KFF maintains full editorial control over all of its policy analysis, polling, and journalism.


Methods

OB-GYN Workforce Analysis:

Information on the OB-GYN workforce is available in HRSA Area Health Resource File (AHRF) for 2021-2022. Data on the OB-GYN workforce is derived from the American Medical Association Physician Masterfiles. Data on the share of the population that is Black non-Hispanic, White non-Hispanic, or Hispanic is based on the 2010 Census Redistricting Data. Data on the share of the population that is foreign-born or that has limited English proficiency is based on the American Community Survey 2016-2020.

County classifications are based on USDA’s 2013 Rural-Urban Continuum Codes, which was the version in use for the 2021-2022 AHRF. This analysis defines metro counties as those in metro areas with any size population; small urban counties as those with a population of 20,000 or more, adjacent or not adjacent to a metro area or that have a population of 2,500-19,999 adjacent to a metro area; and rural counties as those with populations of 2,500-19,999 not adjacent to a metro area or that have a population of less than 2,500, adjacent or not adjacent to a metro area.

It should be noted that clinicians other than OB-GYNs, such as nurse practitioners, physician assistants, and midwives, also provide obstetric and gynecological care and are included in this dataset. However, the dataset does not indicate the specific field in which they practice, so we are unable to include them in this analysis. Doulas, who provide non-clinical support to pregnant and postpartum people, are not generally included in the dataset and so are also not represented in this analysis.

Provider Network Analysis:

This analysis of ACA Marketplace plan networks uses similar methodology as a 2024 KFF analysis. In total, 12 million enrollees selected or were automatically re-enrolled in a plan on either HealthCare.gov (8.3 million) or a state-based Marketplace (3.8 million) during open enrollment for the 2021 plan year. Approximately 55% of enrollees were female and 45% were male. Gender counts for some state-based Marketplaces are incomplete due to unknown or missing gender data; therefore, the data presented in this analysis is representative of Marketplace enrollees of all genders. This analysis estimates the share of OB-GYNs included in individual Marketplace plans in 2021. The data include only physicians (which includes OB-GYNs) and not other providers of obstetric and gynecological care.

Information on plan provider directories was compiled by Ideon through an API with insurers as well as other data including the National Plan and Provider Enumeration System (NPPES). Data for carriers not participating in the Ideon API were supplemented with carriers’ public filings.

Local OB-GYNs are defined as those who practice within the same county as an enrollee or are within the distance thresholds specified as part of CMS’s network adequacy standards for HealthCare.gov plans. See mileage thresholds in Table 1 here for defining “local” areas.  While the mileage standards in network adequacy regulations are based on the proximity to plan enrollees, this analysis measures the distance from the population-weighted center of the county. County classifications (e.g., rural, small urban, metro) were derived from the data source and approach listed in the OB-GYN Workforce Analysis methods section above.

To estimate the total number of OB-GYNs who are in active practice, we relied on Medicare Data on Provider Practice and Specialty (MD-PPAS), a federal database of physicians who submitted at least one Medicare Part B claim in 2021 and therefore saw at least one Medicare patient in the year. Virtually all OB-GYNs participate in Medicare, with only about 1% formally opting out altogether. In total, 34,945 OB-GYNs were included in MD-PPAS in 2021.

Although MD-PPAS provides a list of physicians known to be working, one concern is that a disproportionate share of OB-GYNs may not have treated a Medicare patient in 2021. To assess the representativeness of OB-GYNs in MD-PPAS compared to other physician types, we examined the share of individual providers by specialty in the National Plan and Provider Enumeration System, a federal registry that assigns health care providers unique National Provider Identifiers (but that is not intended to serve as a census of the active health care workforce), who also filed a Medicare Part B claim in MD-PPAS. On average, 61% of OB-GYNs filed a Part B claim—a rate comparable to adult primary care physicians (57%) and all designated physician specialties (58%).

A central challenge in analyzing provider networks is determining the size of the physician workforce. While the vast majority of physicians engaged in active practice accept Medicare, some physicians may be inadvertently missed, including those in closed-network HMOs serving exclusively commercial populations or those specializing in services not typically used by Medicare enrollees. Telehealth providers whose addresses are not within the local market are also excluded. Further, this analysis only considers individual-level physicians enumerated in the plan directory. In some cases, plans may include group health practices in their networks and not individually list providers.

Conversely, this analysis may exaggerate the breadth of provider networks. “Phantom providers,” or physicians who are listed in the plan directory but no longer accept the plan, may artificially increase the breadth of some plans.

Click here to read the full methodology, scope, and limitations of this analysis.

VOLUME 26

States Expand Access to Ivermectin as Cancer Myths Continue, and Abortion Pill Faces False Water Supply Claim


Summary

This volume examines how unsupported claims about ivermectin as a cancer treatment have coincided with legislative efforts to expand access to the drug. It also explores the promotion of unproven “detox” supplements in response to falsehoods about the spike protein from the COVID-19 virus and vaccine, along with the unsubstantiated claim that byproducts from medication abortion pills contaminate the water supply. Lastly, it analyzes the renewed debate over ADHD diagnoses and treatments, including how stigma and shifting policy may affect treatment access.


Recent Developments

State Policy Changes Follow Ongoing Promotion of Ivermectin as Cancer Treatment

Callista Images / Getty Images

Persistent unsupported claims about ivermectin’s effectiveness in treating a range of diseases, including cancer and COVID-19, have coincided with state-level policy efforts to make the drug more accessible. While some studies have suggested ivermectin may enhance the efficacy of chemotherapy and immunotherapy drugs, its use for cancer treatment has not been extensively studied in humans and it is not approved by the Food and Drug Administration (FDA) for this purpose. Oral ivermectin is currently FDA-approved to treat certain parasitic infections in humans, like strongyloidiasis and onchocerciasis, and topical forms are approved to treat head lice and rosacea. Some social media users, though, continue to promote it as a cancer treatment, often sharing personal testimonials that frame the drug as a “miracle cure.” KFF’s monitoring of social media found that the share of cancer-related posts mentioning ivermectin doubled, albeit from a small share to start, in the first half of 2025 compared to all of 2024, with such posts accounting for more than 4% of all cancer-related content identified in our search this year. Between May 28 and June 26, some of the most-engaged-with posts relating to ivermectin as a cancer treatment came from a medical influencer with more than 565,000 followers on X. Their posts called ivermectin a “cutting-edge” cancer treatment and cited anecdotal stories of alleged success treating cancer with ivermectin and other anti-parasitic drugs.

Sixteen states have introduced or passed bills that would make ivermectin available over-the-counter, although pharmacists have expressed reluctance to dispense it without FDA approval for non-prescription or off-label use. Although some share personal stories of themselves or people they know treating their cancer with ivermectin, no major health organizations or regulatory bodies have approved it for cancer treatment, and the use of ivermectin could pose health risks. According to the FDA, ivermectin can interact with other medications, including blood thinners, and overdoses may lead to seizures, coma, or death. Claims that ivermectin can treat cancer may also lead some patients to pursue alternative treatments or delay effective therapies, both of which may result in higher mortality rates.

Polling Insights: KFF polling from 2023 found that about half (48%) of the public has heard the false claim that ivermectin is an effective treatment for COVID-19. While few adults overall say they think this myth is definitely true (6%), seven in ten express uncertainty, saying it is either “probably true” (26%) or “probably false” (44%).

There are notable partisan differences when it comes to believing or leaning toward believing this false claim. About half (48%) of Republicans say it is either “definitely true” or “probably true” that ivermectin is an effective treatment for COVID-19, compared to about three in ten independents (28%) and one in five Democrats (18%).

Few Adults Think the Myth That Ivermectin Can Effectively Treat COVID-19 is Definitely True, But Seven in Ten Express Uncertainty

Unproven “Detoxes” for Spike Protein from COVID-19 Virus and Vaccine Gain Renewed Attention Online

CHRISTOPH BURGSTEDT/SCIENCE PHOTO LIBRARY / Getty Images

Mentions of alleged spike protein “detoxes” have increased on social media, fueled by continued falsehoods that the spike protein produced during COVID-19 exposure or vaccination lingers in the body and causes long-term harm. There is no evidence that the spike protein from vaccines is toxic or remains in the body for an extended period, yet “detox” products continue to be marketed online. The largest volume of social media mentions in 2025, as identified in our search of terms related to spike protein “detoxes,” occurred on May 26, following reports of alleged vaccine-related injuries. Mentions rose again in June when a podcast host posted on X promoting a $90 supplement that claims to “break down spike protein and disrupt its function.” In reality, the spike protein produced by an mRNA vaccine only attaches to the outer layer of cells to trigger an immune response against future illness and typically clears from the body after a few days.

A popular “detox” formula, which is marketed by a medical doctor whose credentials were revoked for promoting false claims about COVID-19 vaccines, contains nattokinase, bromelain, and curcumin. These supplements are generally considered safe, but their use as spike protein detoxes lacks scientific support and may carry risks. Nattokinase and bromelain have blood-thinning properties that can interact with anticoagulant or antiplatelet medications, potentially increasing the risk of excessive bleeding. Curcumin may pose similar risks and has been associated with liver injury in some cases. Infectious disease doctors warn that promoting unnecessary and potentially harmful “detox” products may further erode public trust in the safety of COVID-19 vaccines.

Abortion Opponents Fabricate Concerns About Water Contamination in Effort to Restrict Access to Abortion Pills

KFF / Getty Images

The baseless narrative that medication abortion pills, particularly mifepristone, contaminate the water supply through urine and menstrual blood is circulating online alongside unfounded claims that abortion pill byproduct in water systems can lead to negative impacts on fertility, public health, and the environment. Federal agencies and independent researchers have found no evidence that mifepristone contaminates the water supply at levels that cause harm, but unsupported claims have appeared sporadically over the past few years, recently gaining traction in late June.

On June 17, a report from an advocacy group that opposes abortion access alleged that over 40 tons of fetal remains and abortion pill byproducts have entered the water system, potentially causing infertility and other reproductive health problems. The report did not include any evidence to substantiate the allegation. While the report was not covered by major news outlets, it circulated widely through non-mainstream news, anti-abortion advocacy groups, and policymakers who called for federal agencies to test the water supply for abortion pill byproducts. The following day, twenty-five House and Senate Republicans signed a letter to the Environmental Protection Agency (EPA) calling for an investigation into the matter. Later, a video clip circulated widely online of a U.S. congresswoman who opposes abortion stating, without evidence, that the water supply is “severely contaminated” by abortion drugs. Social media users who shared the clip amplified the claim, including one X user with more than 259,000 followers. Others questioned the legitimacy of the claim by noting that the FDA and environmental scientists have found no basis for this claim.

An environmental assessment conducted as a part of the FDA’s approval process for the drug estimated its environmental concentration to be less than one part per billion – an amount considered too low to affect standard test organisms. The FDA has described that estimate as conservative because it does not account for metabolism of the drug by the human body or the ability of wastewater treatment plants to remove pharmaceuticals from water. Despite a lack of evidence of harm, state lawmakers in Wyoming and Texas introduced bills earlier this year aiming to mandate testing of water supplies for excreted fetal tissue and abortion medication byproduct. As access to mifepristone remains at risk, these narratives and legislative efforts may contribute to further restrictions on abortion access through arguments not grounded in science and unrelated to medical safety or reproductive rights. Additionally, elevating these unproven claims to call for a federal investigation, despite the lack of scientific basis, could further erode trust in public health institutions and regulatory bodies.

Debate Over ADHD Medication Resurfaces on Social Media

AndreyPopov / Getty Images

Concerns about the overmedicalization of attention-deficit hyperactivity disorder (ADHD) have existed for decades, with the scientific community divided over how often the condition is overdiagnosed or overtreated. The ongoing debate coincides with rising diagnoses, although nearly one-third of those diagnosed receive no treatment. A 2021 scoping review found evidence of overdiagnosis and overtreatment, particularly among youth with mild symptoms, but other literature attributes rising diagnoses to shifting diagnostic criteria, greater public awareness, and historic disparities in underrepresented populations.

The long-running public debate was renewed by the resurfacing of a 2005 interview with actor Tom Cruise, who criticized the legitimacy of psychiatric diagnoses and pharmaceutical treatments. The video, reposted in late May, became the most shared post on X identified through our search of terms related to ADHD medications between May 27 and June 25. Some users praised Cruise’s skepticism and repeated claims that pharmaceutical companies have over-influenced mental health care. Others repeated stigmatizing claims about ADHD medication, including linking it to violence, despite multiple studies showing that ADHD medications reduce the risk of criminality, self-harm, and other adverse outcomes. These narratives may contribute to stigma around ADHD and its treatment, potentially dissuading individuals or parents from seeking or continuing treatment. Claims of overmedicalization have also influenced recent policy discussions. A May report from the White House’s Make America Healthy Again (MAHA) Commission identified overmedicalization as a key factor in childhood chronic disease. The report further claimed that there is evidence that ADHD medications do not improve long-term outcomes, but ADHD specialists and advocacy groups have argued that the research cited is flawed and does not account for changes in medication practices. Proposed changes by the Drug Enforcement Administration (DEA) to its telemedicine rules have also raised concern about access to ADHD medication. The agency said it received 38,000 comments on its proposed rules, many of which expressed concern that the changes might limit availability. Nearly half of adults with ADHD reported having used telehealth to receive treatment.


AI & Emerging Technology

Study Finds Small Language Changes Can Alter AI Medical Advice

Abdullah Durmaz / Getty Images

As medical providers seek to incorporate artificial intelligence (AI) tools in clinical environments, new research from the Massachusetts Institute of Technology (MIT) finds that large language models (LLMs) may generate inconsistent medical advice to users based on small changes to patient messages, like including typos, extra white spaces, or colloquial language. Researchers tested four commonly used LLMs by introducing minor, non-clinical language changes designed to simulate messages that might be written by different patient populations seeking advice from these models. This included people with limited English proficiency or health anxiety.

Across all of the altered messages, LLMs were 7-9% more likely to recommend self-management solutions rather than seeking medical care. The study compared these recommendations to those of clinicians and found that in many cases, the AI suggested self-management when providers would recommend escalating medical care. The effect was amplified for women, with researchers noting that the models made about 7% more errors for female patients and were more likely to recommend self-management. Researchers cautioned that the models’ sensitivity to irrelevant linguistic cues, particularly those designed to mimic vulnerable populations, could lead to uneven care recommendations and reinforce health disparities.

About The Health Information and Trust Initiative: the Health Information and Trust Initiative is a KFF program aimed at tracking health misinformation in the U.S., analyzing its impact on the American people, and mobilizing media to address the problem. Our goal is to be of service to everyone working on health misinformation, strengthen efforts to counter misinformation, and build trust. 


View all KFF Monitors

The Monitor is a report from KFF’s Health Information and Trust initiative that focuses on recent developments in health information. It’s free and published twice a month.

Sign up to receive KFF Monitor
email updates


Support for the Health Information and Trust initiative is provided by the Robert Wood Johnson Foundation (RWJF). The views expressed do not necessarily reflect the views of RWJF and KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities. The data shared in the Monitor is sourced through media monitoring research conducted by KFF.

Donor Government Funding for HIV in Low- and Middle-Income Countries in 2024

Authors: Adam Wexler, Jennifer Kates, and Eric Lief
Published: Jul 10, 2025

Overview

This report, Donor Government Funding for HIV in Low- and Middle-Income Countries in 2024, tracks funding levels of the donor governments that collectively provide the bulk of international assistance for AIDS through bilateral programs and contributions to multilateral organizations. The new report, produced as a partnership between KFF and UNAIDS, provides the latest data available on donor funding disbursements based on data provided by governments. It includes their bilateral assistance to low- and middle-income countries and contributions to the Global Fund to Fight AIDS, Tuberculosis and Malaria as well as UNITAID.

Previous versions by publish date:

July 2023 (.pdf)

July 2022 (.pdf)

July 2021 (.pdf)

July 2020 (.pdf)

July 2019 (.pdf)

July 2018 (.pdf)

July 2017 (.pdf)

July 2016 (.pdf)

July 2015 (.pdf)

July 2014 (.pdf)

September 2013 (.pdf)

July 2012 (.pdf)

July 2011 (.pdf)

July 2010 (.pdf)

July 2009 (.pdf)

July 2008 (.pdf)

June 2007 (.pdf)

July 2006 (.pdf)

July 2005 (.pdf)

Key Findings

In 2025, the donor government funding landscape fundamentally changed. Under the new administration, the United States, the largest donor to HIV in the world, has instituted significant changes to global health programs including freezing, and then cancelling, most global HIV projects, restricting allowable activities, and seeking to cut HIV funding by at least 40%, actions which have collectively driven down disbursements. In addition, several other large donors to HIV – the United Kingdom, Germany and France – have also signaled reductions in their development assistance budgets. As such, this report, which focuses on both bilateral and multilateral funding for HIV provided by donor governments in 2024 and shows an increase over 2023, is likely the high watermark as funding will likely decline moving forward. While the U.S. has shouldered much of the burden of funding the HIV response, its abrupt reductions leave large gaps and could set back the HIV response, as some studies have already found. Key findings are as follows:

  • Donor government funding for HIV increased in 2024 compared to the prior year. Disbursements for combined bilateral and multilateral support were US$8.37 billion in 2024, an increase of US$460 million compared to 2023 (US$7.91 billion), in current U.S. dollars (not adjusted for inflation).1  Funding increased even after accounting for exchange rate fluctuations. Looking more broadly, donor government funding for HIV in 2024 was at its highest level since 2014 (US$8.60 billion), but still below that peak.
  • The increase in 2024 was almost entirely due to the timing of disbursements by the U.S., not actual changes in funding commitments. The timing of disbursements, or payouts, by donor governments fluctuates each year and those fluctuations can affect overall levels of funding availability, independent of donor funding commitments. In 2024, the U.S. government’s disbursements for HIV increased significantly, while the U.K.’s payout declined, but both were due to the timing of payouts. Other donors had similar fluctuations. Because the U.S. is the largest donor, its fluctuations drove up overall funding levels in 2024.
  • Bilateral funding increased in 2024, driven by payout timing. Bilateral funding totaled US$5.87 billion in 2024, an increase of US$241 million compared to 2023 (US$5.63 billion), with five donors providing increased disbursements. The increase was primarily the result of higher funding from the U.S., due to the timing of payouts, and the U.K., as well as slight increases from Australia, Japan, and Norway. Funding from eight donor governments decreased and two remained flat.
  • Multilateral funding, which is the main channel of support for HIV used by most donor governments, also increased in 2024, similarly due to the timing of contributions. Multilateral funding totaled US$2.50 billion in 2024, an increase of US$218 million compared to 2023 (US$2.28 billion). Six donor governments increased multilateral support, while four remained flat, and five declined. Most multilateral funding for HIV was provided to the Global Fund (US$2.27 billion or 91%) with smaller amounts provided to UNAIDS (US$169 million or 7%) and UNITAID (US$59 million or 2%). The timing of payments to the Global Fund drove the multilateral increase in 2024.
  • The U.S. has consistently been the largest donor to HIV. In 2024, the U.S. provided US$6.69 billion for HIV (bilateral and multilateral combined), accounting for 80% of total donor government support.2  France was the second largest donor (US$314 million, 4%), followed by Germany (US$226 million, 3%), the U.K. (US$218 million, 3%), and the Netherlands (US$192 million, 2%).3 ,4  Even when standardized by the size of its economy (per million GDP), the U.S. ranked first. The next largest donor, per million GDP, was the Netherlands, followed by Denmark, France, and Norway.

Looking ahead, donor government funding for HIV is expected to decline in 2025 and beyond. Due to the new administration’s actions targeting U.S. foreign assistance programs, including for global health and HIV, U.S. disbursements for HIV this year are well below prior year levels.5  In addition, the administration has asked Congress to rescind (formerly cancel) approximately US$400 million in bilateral HIV funding for 2025 and has proposed reducing the HIV budget by at least 40% in 2026. If these cuts were to materialize, other donor governments would have to more than double their HIV funding to maintain current levels. Given that the U.S. has already reduced HIV spending in 2025 and several other large donors have announced plans to reduce foreign assistance, funding for HIV in low- and middle-income countries is highly likely to decline.

Report

Introduction

This report provides the latest available data on donor government resources provided to address HIV in low- and middle-income countries, reporting on disbursements made in 2024. It is part of a collaborative tracking effort between UNAIDS and KFF that began almost 20 years ago, just as new global initiatives were being launched to address the epidemic. The analysis includes data from all 33 members of the Organisation for Economic Co-operation and Development (OECD)’s Development Assistance Committee (DAC), as well as non-DAC members who report data to the DAC. Data are collected directly from donor governments, UNAIDS, the Global Fund, and UNITAID, and supplemented with data from the DAC. Of the 33 DAC members, fifteen provide 98% of total disbursements for HIV; data for these donors are presented individually. For the remaining 18 DAC members, data are provided in aggregate. All totals are presented in current U.S. dollars (amounts are not adjusted for inflation). While totals include both bilateral and multilateral assistance for the entire period (2002-2024), detailed disaggregated bilateral and multilateral amounts for all donors are only available starting in 2011 (see Methodology for more detail).

Importantly, given that the donor government funding landscape fundamentally changed in 2025, the data provided here likely represent a high watermark for HIV funding. Under the new administration, the United States, the largest donor to HIV in the world, began instituting significant changes to global health programs in January 2025, including freezing, and then cancelling, most global HIV projects, restricting allowable activities, and seeking to cut HIV funding by at least 40%, actions which have collectively driven down disbursements. If U.S. reductions continue and future cuts were to be enacted, other donor governments would have to more than double their funding to maintain current levels. Yet several other large donors to HIV – the United Kingdom, Germany and France – have also signaled reductions in their development assistance budgets, making it highly likely that future funding will be reduced.

Findings

Total Funding

In 2024, donor government funding for HIV through bilateral and multilateral channels totaled US$8.37 billion in current USD (not adjusted for inflation) and accounted for approximately 44% of the US$18.7 billion estimated by UNAIDS to be available to address HIV.6 ,7 ,8 ,9  As per UNAIDS estimates, domestic resources accounted for 52%, and the remainder (4%) was from foundations, other multilateral organizations, and UN agencies.

Donor government funding for HIV in 2024 increased by US$460 million compared to 2023 (US$8.37 in 2024 compared to US$7.91 billion in 2023) and reached the highest level since 2014 (US$8.60 billion), though it is still below that highpoint (See Figure 1 and Table 1).10 

HIV Funding from Donor Governments, 2002-2024

Donor Government Funding for HIV (bilateral & multilateral), 2011-2024 (current USD in millions)

The increase in 2024 was almost entirely due to the timing of disbursements, or payouts, by donor governments, which can fluctuate from year-to-year, not actual changes in funding commitments. For instance, U.S. disbursements increased significantly in 2024 while funding from the U.K. declined, but both were due to the timing of payouts. As two of the world’s largest donors, these fluctuations can have an outsized impact on the overall amount of available funding in a given year.

The U.S. continued to be the largest donor to HIV efforts, providing US$6.69 billion and accounting for 80% of total donor government funding in 2024.11  The second largest donor was France (US$314 million, 4%), followed by Germany (US$226 million, 3%), the U.K. (US$218 million, 3%), and the Netherlands (US$192 million, 2%).12 ,13  In 2024, 91% of total donor government funding for HIV was provided by these five donors.

Bilateral Disbursements

Bilateral disbursements for HIV from donor governments – that is, funding disbursed by a donor on behalf of a recipient country or region – totaled US$5.87 billion in 2024, an increase of US$241 million compared to 2023 (US$5.63 billion). Despite the increase, bilateral funding from most donor governments decreased or remained flat and most of the overall increase was attributable to the U.S. and the U.K. When the increases from the U.S. and U.K. are removed, bilateral funding from all other donor governments declined by US$49 million in 2024 (US$237 million) compared to 2023 (US$286 million). These trends were the same after accounting for exchange rate fluctuations.

Bilateral disbursements from the U.S. increased by almost US$200 million in 2024 (US$5.43 billion) compared to 2023 (US$5.23 billion), due to the timing of payouts, but not actual increases in funding commitments. In fact, bilateral HIV funding as specified by the U.S. Congress in annual appropriations bills has been flat for several years (see Figure 2).14 ,15 

Bilateral HIV Funding from the United States, Appropriations vs. Disbursements, 2011-2024

Multilateral Contributions

Multilateral contributions from donor governments to the Global Fund, UNITAID, and UNAIDS for HIV – funding disbursed by donor governments to these organizations which in turn use some (Global Fund and UNITAID) or all (UNAIDS) of that funding for HIV – totaled US$2.50 billion in 2024 (after adjusting for an HIV share to account for the fact that the Global Fund and UNITAID address other diseases). This represents an increase of US$218 million compared to 2023 (US$2.28 billion).16 ,17  The Global Fund accounted for most of the multilateral funding for HIV in 2024 (US$2.27 billion or 91%), followed by UNAIDS (US$169 million or 7%) and UNITAID (US$59 million or 2%).

The increase in 2024 disbursements was due to the timing of payments to the Global Fund, particularly from the U.S., which is required by law not to exceed 33% of total contributions to the Global Fund from all donors and results in significant year-to-year differences depending on the amounts other donors have provided.18  In addition, funding from donor governments to the Global Fund often fluctuates reflecting different Global Fund pledge periods. For instance, some donors choose to “front-load” contributions (e.g., the U.K. fulfilled almost its entire pledge for 2023-2025 in 2023 resulting in a significant decrease in 2024), while others choose to fulfill pledges towards the end of the pledge period (e.g., Australia and Denmark did not provide any contribution in 2023, but both fulfilled more than half their pledges in 2024).

Most donor governments provide the majority of their HIV funding through multilateral organizations. In 2024, eleven provided more than 80% of their HIV funding multilaterally; only Denmark, the Netherlands, the U.K., and the U.S. provided a larger share bilaterally (Figure 3). While the U.K. provided most of its HIV funding bilaterally in 2024, this was entirely due to the timing of payments to the Global Fund. The U.K. fulfilled almost its entire pledge to the Global Fund for 2023-205 in 2023 resulting in significantly lower levels of multilateral funding in 2024. In fact, between 2019-2023, most HIV funding from the U.K. was provided through multilateral channels.

HIV Funding from Donor Governments by Funding Channel, 2024

Fair Share

There are different ways to measure donor government contributions to HIV, relative to one another. While the U.S. government provides the largest amount of funding for HIV, for example, it also has the largest economy in the world. To assess relative contributions, or “fair share”, two measures were used: ranking by overall funding amount and ranking by funding for HIV per US$1 million GDP, to adjust for the size of donor economies (See Table 2):

  • Rank by share of total donor government funding for HIV: By this measure, the U.S. ranked first in 2024, followed France, Germany, the U.K., and the Netherlands. The U.S. has ranked #1 in absolute funding amounts since tracking efforts began.
  • Rank by funding for HIV per US$1 million GDP: By this measure, the U.S. ranks first, followed by the Netherlands, Denmark, France, and Norway (See Figure 4).19 

Assessing Fair Share Across Donor Governments, 2024

Donor Government Ranking by Funding for HIV per US$1 Million GDP, 2024

Looking Forward

Donor government funding for HIV in low and middle-income countries is likely to decline in 2025. While the anticipated decline is largely due to actions by the new administration, which have already resulted in lower disbursements in 2025, other donor governments have also indicated plans to reduce foreign assistance. Looking beyond 2025, the new administration has proposed to reduce HIV funding by at least 40% in 2026. Since the U.S. is the world’s largest donor to the global HIV response, a cut in funding of this size would require other donor governments to more than double their funding to fill the gap, an increase that seems unlikely. While final funding amounts are determined by the U.S. Congress, the administration’s actions may continue to have the effect of reducing HIV funding from the U.S.

This work was supported in part by the Joint United Nations Programme on HIV and AIDS (UNAIDS) and the Bill & Melinda Gates Foundation. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.

Adam Wexler and Jen Kates are with KFF. Eric Lief is an independent consultant. Joint United Nations Programme on HIV and AIDS (UNAIDS).

Methodology

This project represents a collaboration between the Joint United Nations Programme on HIV/AIDS (UNAIDS) and KFF. Data provided in this report were collected and analyzed by UNAIDS and KFF.

Totals presented in this analysis include both bilateral funding for HIV in low- and middle-income countries, core contributions to UNAIDS, and the estimated share of donor government contributions to the Global Fund and UNITAID that are used for HIV. Amounts are based on analysis of data from the 32 donor government members of the Organisation for Economic Co-operation and Development (OECD) Development Assistance Committee (DAC) in 2024 who had reported Official Development Assistance (ODA). Bilateral and multilateral data were collected from multiple sources. Disaggregated bilateral and multilateral data are only available starting from 2011.

Data on gross domestic product (GDP) were obtained from the International Monetary Fund’s World Economic Outlook Database and represent current price data for 2024 (see: https://www.imf.org/en/Publications/WEO/weo-database/2025/April).

Bilateral Funding:Bilateral funding is defined as any earmarked (HIV-designated) amount, including earmarked non-core (“multi-bi”) contributions to multilateral organizations, such as UNAIDS. Data included in this report represent funding assistance for HIV prevention, care, treatment and support activities, but do not include funding for international HIV research conducted in donor countries (which is not considered in estimates of resource needs for service delivery of HIV-related activities).

The research team collected the latest bilateral funding data directly from twelve governments: Australia, Canada, Denmark, France, Germany, Ireland, Japan, the Netherlands, Norway, Sweden, the United Kingdom, and the United States during the first half of 2025, representing the fiscal year 2024 period. Direct data collection from these donors was desirable because they represent the preponderance of donor government assistance for HIV and the latest official statistics – from the Organisation for Economic Co-operation and Development (OECD) Creditor Reporting System (CRS) (see: http://www.oecd.org/dac/stats/data) – are from 2023 and do not include all forms of international assistance (e.g., certain funding streams provided by donors, such as HIV components of mixed-purpose grants to non-governmental organizations). Data for all other member governments of the OECD DAC – Austria, Belgium, the Czech Republic, the European Commission, Estonia, Finland, Greece, Hungary, Iceland, Italy, Korea, Lithuania, Luxembourg, New Zealand, Poland, Portugal, the Slovak Republic, Slovenia, Spain, and Switzerland – which collectively accounted for less than 5 percent of bilateral disbursements in each of the past several years, were obtained from the OECD CRS database and are from calendar year 2023.

In 2025, France provided data revising prior year amounts to account for “set-aside” funding (adjusted for an HIV-share) that supports Global Fund related activities. While this funding is considered part of France’s pledge to the Global Fund, it is not counted by the Global Fund as a direct contribution and is instead included under bilateral totals in this analysis. Due to this update, amounts presented in this report will differ from prior reports.

Where donor governments were members of the European Union (EU), the research team ensured that no double-counting of funds occurred between EU Member State reported amounts and European Commission (EC) reported amounts for international HIV assistance. Figures obtained directly using this approach should be considered as the upper bound estimation of financial flows in support of HIV-related activities.

Reflecting deliberate strategies of integrating HIV activities into other activity sectors, some donors use policy markers to attribute portions of mixed-purpose projects to HIV. This is done, for example, by the Netherlands and the U.K. The bilateral figures submitted by the UK Foreign, Commonwealth & Development Office (FCDO) for the financial year 2024/25 are based on an existing FCDO ‘HIV policy marker’. Ireland and Denmark also attribute percentages of multipurpose projects to HIV. Canada breaks its mixed-purpose projects into components by percentage. Germany, Norway, and Sweden provided data much more conservatively, consistent with DAC constructs and purpose codes. Apart from targeted HIV/AIDS programs, bilateral health programs mainly focusing on health systems strengthening are also designed to contribute to the HIV response in partner countries.

Bilateral assistance data represent disbursements. A disbursement is the actual release of funds to, or the purchase of goods or services for, a recipient. Disbursements in any given year may include disbursements of funds committed in prior years and in some cases, not all funds committed during a government fiscal year are disbursed in that year. In addition, a disbursement by a government does not necessarily mean that the funds were provided to a country or other intended end-user.

Amounts presented are for the fiscal year period, which varies by country. The U.S. fiscal year runs from October 1-September 30. The fiscal years for Canada, Japan, and the U.K. are April 1-March 31. The Australian fiscal year runs from July 1-June 30. The European Commission, Denmark, France, Germany, Italy, Ireland, the Netherlands, Norway, and Sweden use the calendar year. The OECD uses the calendar year, so data collected from the CRS for other donor governments reflect January 1-December 31. Most UN agencies use the calendar year, and their budgets are biennial.

All data are expressed in current US dollars (USD), unless otherwise noted. Where data were provided by governments in their currencies, they were adjusted by average daily exchange rates to obtain a USD equivalent, based on foreign exchange rate historical data available from the U.S. Federal Reserve (see: http://www.federalreserve.gov/) or the OECD.

Funding totals presented in this analysis should be considered preliminary estimates based on data provided and validated by representatives of the donor governments who were contacted directly.

Multilateral Funding:Multilateral funding includes core contributions to UNAIDS, as well as contributions to the Global Fund (see: http://www.theglobalfund.org/en/) and UNITAID (see: http://www.unitaid.org/#end). All Global Fund contributions were adjusted to represent 52% of the donor’s core contribution, reflecting the Fund’s reported grant approvals for HIV-related projects to date and includes funding for HIV/TB activities. UNITAID contributions were adjusted to represent 46% of the donor’s core contribution, reflecting UNITAID’s reported attribution for HIV-related projects.

Data obtained from UNAIDS, the Global Fund, and UNITAID were already adjusted to represent a USD equivalent based on date of receipts.

UNAIDS core contributions reflect amounts received in 2024. In 2024, the Netherlands provided two core contributions to UNAIDS; the first payment was provided for the 2024 contribution, while the second was a prepayment of the 2025 contribution. Global Fund and UNITAID contributions from all governments correspond to amounts received during the 2024 calendar year, regardless of which contributor’s fiscal year such disbursements pertain to.

In addition to contributions supporting the Global Fund’s and UNITAID’s core activities, some donor governments provided significant funding to these multilateral organizations for COVID-related efforts between 2020-2023. These COVID-specific contributions were not included in totals in this analysis. The U.S., for example, provided almost US$1.9 billion in such funding to the Global Fund during 2022.

Other than contributions provided by governments to the Global Fund and UNITAID, un-earmarked general contributions to United Nations entities, most of which are membership contributions set by treaty or other formal agreement (e.g., the World Bank’s International Development Association or United Nations country membership assessments), are not identified as part of a donor government’s HIV assistance even if the multilateral organization in turn directs some of these funds to HIV. Rather, these would be considered as HIV funding provided by the multilateral organization, as in the case of the World Bank’s efforts, and are not considered for purposes of this report.

Appendix

Donor Government Funding for HIV (current USD in millions), 2023 & 2024

Endnotes

  1. Between 2020-2023, some donor governments provided COVID-specific emergency contributions to the Global Fund and UNITAID in addition to their contributions for core activities. For the purposes of this report, these COVID-specific amounts have been excluded as they cannot be attributed to a specific area, such as HIV. ↩︎
  2. U.S. totals represent funding amounts provided through regular appropriations only. In 2021, the U.S. Congress appropriated additional emergency supplemental funding for bilateral HIV activities and for the Global Fund to address the impacts of the COVID-19 pandemic. These emergency supplemental funding amounts are not included in overall U.S. totals. ↩︎
  3. In 2025, France provided data revising prior year amounts to account for “set-aside” funding (adjusted for an HIV-share) that supports Global Fund related activities. While this funding is considered part of France’s pledge to the Global Fund, it is not counted by the Global Fund as a direct contribution and is instead included under bilateral totals in this analysis. Due to this update, amounts presented in this report will differ from prior reports. ↩︎
  4. Total HIV funding from the Netherlands in 2024 includes two core contributions to UNAIDS; the first payment was provided for the 2024 contribution, while the second was a prepayment of the 2025 contribution. ↩︎
  5. KFF analysis of data from USAspending.gov and Treasury.gov. ↩︎
  6. Donor government disbursements are a subset of overall international assistance for HIV in low-and-middle-income countries, which also includes funding provided by other multilateral institutions, UN agencies, and foundations. ↩︎
  7. UNAIDS, “UNAIDS Global AIDS Update 2025: AIDS, Crisis and the Power to Transform”, July 2025. ↩︎
  8. UNAIDS estimates that US$18.7 billion was available for HIV from all sources (domestic resources, donor governments, multilaterals, and philanthropic organizations) in 2024. In addition, while the amounts presented in this analysis include donor contributions to multilateral organizations, the UNAIDS estimate of total available resources for HIV includes the actual disbursements made by multilateral organizations in 2024 rather than the donor government contributions to these entities. ↩︎
  9. The donor share of total available resources includes bilateral disbursements as well as an adjusted share of Global Fund and UNITAID disbursements (the donor government share of contributions to each of the multilaterals in 2024 is applied to the disbursements from these multilaterals for the same year). ↩︎
  10. KFF & UNAIDS, “Donor Government Funding for HIV in Low- and Middle-Income Countries in 2023”, July 2024. ↩︎
  11. U.S. totals represent funding amounts provided through regular appropriations only. In 2021, the U.S. Congress appropriated additional emergency supplemental funding for bilateral HIV activities and for the Global Fund to address the impacts of the COVID-19 pandemic. These emergency supplemental funding amounts are not included in overall U.S. totals. ↩︎
  12. In 2025, France provided data revising prior year amounts to account for “set-aside” funding (adjusted for an HIV-share) that supports Global Fund related activities. While this funding is considered part of France’s pledge to the Global Fund, it is not counted by the Global Fund as a direct contribution and is instead included under bilateral totals in this analysis. Due to this update, amounts presented in this report will differ from prior reports. ↩︎
  13. Total HIV funding from the Netherlands in 2024 includes two core contributions to UNAIDS; the first payment was provided for the 2024 contribution, while the second was a prepayment of the 2025 contribution. ↩︎
  14. KFF, “The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)”, May 2025. ↩︎
  15. U.S. totals represent funding amounts provided through regular appropriations only. In 2021, the U.S. Congress appropriated additional emergency supplemental funding for bilateral HIV activities and for the Global Fund to address the impacts of the COVID-19 pandemic. These emergency supplemental funding amounts are not included in overall U.S. totals. ↩︎
  16. Between 2020-2023, some donor governments provided COVID-specific emergency contributions to the Global Fund and UNITAID in addition to their contributions for core activities. For the purposes of this report, these COVID-specific amounts have been excluded as they cannot be attributed to a specific area, such as HIV. ↩︎
  17. In 2024, 52% of the Global Fund’s disbursements and 48% of UNITAID’s disbursements were directed to HIV activities. These percentages were applied to the full donor government contributions to these multilateral organizations to calculate the “HIV-share” (see Methodology for additional details). ↩︎
  18. The U.S. has had a long-standing legislative requirement that total U.S. contributions to the Global Fund could not exceed 33% of all contributions (see “KFF – The U.S. & The Global Fund to Fight AIDS, Tuberculosis and Malaria”), which results in year-to-year fluctuations in U.S. payouts to the Global Fund depending on when other donors provide funds. However, this requirement technically expired in March when the authorization legislation ended (see “KFF – PEPFAR Reauthorization: Side-by-Side of Legislation Over Time”). ↩︎
  19. GDP estimates are from the International Monetary Fund’s (IMF) World Economic Outlook (WEO) Database (accessed July 2025). ↩︎

Health Provisions in the 2025 Federal Budget Reconciliation Bill

Updated: July 8, 2025


Note: KFF now has a clean summary of the health care provisions in the 2025 federal budget reconciliation law as well as a separate implementation timeline highlighting key dates in the law.

This side-by-side comparison tool compares the health care provisions in the House-passed and Senate-passed 2025 budget reconciliation law to each other and prior law. The Senate-passed bill ultimately passed the House on July 3 and was signed into law by President Trump on July 4. The comparison is divided into four categories: Medicaid, the Affordable Care Act, Medicare and Health Savings Accounts (HSAs). It also compares the provisions to a earlier draft of the bill passed by the House on May 22.

Summary of House Reconciliation Bill

Topics:

Health Provisions in the 2025 Federal Budget Reconciliation Bill

Updated: July 8, 2025


Note: KFF now has a clean summary of the health care provisions in the 2025 federal budget reconciliation law as well as a separate implementation timeline highlighting key dates in the law.

This side-by-side comparison tool compares the health care provisions in the House-passed and Senate-passed 2025 budget reconciliation law to each other and prior law. The Senate-passed bill ultimately passed the House on July 3 and was signed into law by President Trump on July 4. The comparison is divided into four categories: Medicaid, the Affordable Care Act, Medicare and Health Savings Accounts (HSAs). It also compares the provisions to a earlier draft of the bill passed by the House on May 22.

Summary of HSA-Related Provisions in 2025 Reconciliation Bill

Health Provisions in the 2025 Federal Budget Reconciliation Bill

Updated: July 8, 2025


Note: KFF now has a clean summary of the health care provisions in the 2025 federal budget reconciliation law as well as a separate implementation timeline highlighting key dates in the law.

This side-by-side comparison tool compares the health care provisions in the House-passed and Senate-passed 2025 budget reconciliation law to each other and prior law. The Senate-passed bill ultimately passed the House on July 3 and was signed into law by President Trump on July 4. The comparison is divided into four categories: Medicaid, the Affordable Care Act, Medicare and Health Savings Accounts (HSAs). It also compares the provisions to a earlier draft of the bill passed by the House on May 22.

In addition to the changes included in the law, if Congress takes no further action, the increase in the deficit would trigger mandatory spending cuts, also known as sequestration, under the Statutory Pay-As-You-Go Act of 2010. These cuts would total approximately $500 billion to Medicare over 2026–2034, according to the Congressional Budget Office, based on an increase in the deficit of $2.3 trillion over 10 years. The required spending cuts to Medicare could be larger based on the Senate-passed bill that was enacted into law, which is estimated to increase the deficit by $3.4 trillion over 10 years

Summary of Medicare Provisions in 2025 Reconciliation Bill

Health Provisions in the 2025 Federal Budget Reconciliation Bill

Updated: July 8, 2025


Note: KFF now has a clean summary of the health care provisions in the 2025 federal budget reconciliation law as well as a separate implementation timeline highlighting key dates in the law.

This side-by-side comparison tool compares the health care provisions in the House-passed and Senate-passed 2025 budget reconciliation law to each other and prior law. The Senate-passed bill ultimately passed the House on July 3 and was signed into law by President Trump on July 4. The comparison is divided into four categories: Medicaid, the Affordable Care Act, Medicare and Health Savings Accounts (HSAs). It also compares the provisions to a earlier draft of the bill passed by the House on May 22.

Summary of ACA-Related Provisions in the 2025 Reconciliation Bill

We’ve Never Seen Health Care Cuts This Big

Author: Larry Levitt
Published: Jul 1, 2025

In this July 1 column for The New York Times Opinion section, KFF Executive Vice President for Health Policy Larry Levitt explains how the budget reconciliation bill passed by the Senate on July 1 is effectively a partial repeal of the Affordable Care Act (ACA) and, if signed into law, the resulting reductions in Medicaid and ACA Marketplace coverage would make it “the biggest rollback in federal support for health coverage ever.”